

# Understanding Nipah Virus Infection: A Comprehensive Overview

Rama Danapure\*

## Abstract

*Nipah virus (NiV) infection is a zoonotic disease caused by the Nipah virus, primarily found in bats of the Pteropus genus. Since its identification in 1999 during an outbreak in Malaysia, NiV has emerged as a significant public health concern, particularly in Southeast Asia. This abstract provides a comprehensive overview of Nipah virus infection, covering its epidemiology, transmission, clinical manifestations, diagnosis, treatment, prevention, and global health implications. Epidemiology: Nipah virus outbreaks have been reported in various countries, including Singapore, India, Malaysia, and Bangladesh. Fruit bats serve as the natural reservoir of NiV, with transmission to humans typically occurring through the consumption of contaminated fruits or direct exposure to bat excreta. Transmission: Human-to-human transmission of the Nipah virus (NiV) primarily occurs through close contact with infected individuals or their bodily fluids. Nosocomial transmission has been documented during outbreaks, underscoring the critical need for infection control measures in healthcare settings. Clinical manifestations of NiV infection vary widely, ranging from mild febrile illness to severe respiratory and neurological complications, such as encephalitis. The case-fatality rates during outbreaks can vary widely, ranging from 40% to 100%. Diagnosis and Treatment: Diagnosing NiV infection can be difficult because its clinical symptoms are not specific. Laboratory testing, including molecular assays and serological methods, is essential for accurate diagnosis. Currently, there are no specific antiviral treatments for NiV infection, and management mainly involves providing supportive care to alleviate symptoms and complications. Prevention and Control: Preventing Nipah virus outbreaks requires a multifaceted approach, including surveillance of bat populations, early detection of cases, rapid response to outbreaks, and implementation of infection control measures in healthcare settings. Vaccines and antiviral drugs targeting NiV are under development, offering promising avenues for future prevention and treatment efforts. Global Health Implications: Nipah virus infection poses significant challenges to global health security due to its potential for international spread and high case-fatality rates. Cooperation between nations and international organizations is crucial for the effective prevention and management of NiV outbreaks.*

**Keywords:** Nipah virus, Zoonotic disease, epidemiology, transmission, public health

### \*Author for Correspondence

Rama Danapure  
E-mail: ramaschate7@gmail.com

Associate Professor, Department of Community Health Nursing Maharishi Karve Stree Shikashan Samastha, Sitabai Nargundkar College of Nursing for Women Nagpur, India

Article Received: May 22, 2024  
Article Accepted: June 03, 2024  
Article Published: October 09, 2024

**Citation:** Rama Danapure. Understanding Nipah Virus Infection: A Comprehensive Overview. International Journal of Animal Biotechnology and Applications. 2024; 10(1): 18–22p.

## INTRODUCTION

Nipah virus (NiV) infection is a zoonotic disease that poses a significant threat to public health, particularly in parts of Southeast Asia, where outbreaks have occurred periodically since its discovery in 1999. This article provides a detailed overview of Nipah virus infection, including its epidemiology, transmission, clinical manifestations, diagnosis, treatment, prevention, and broader implications for global health.

Between September 12th and 15, 2023, the Ministry of Health and Family Welfare, Government

of India, confirmed six cases of Nipah virus in the Kozhikode district, Kerala, resulting in two fatalities. While the source of infection remained unknown for the initial case, subsequent cases were identified as family members and hospital contacts of the index case. As of September 27, 2023, health authorities have traced 1288 contacts of confirmed cases, including high-risk individuals and healthcare workers who are undergoing a 21-day quarantine and monitoring period [1]. Over the same period, 387 samples were tested, revealing six positive cases of Nipah virus infection, with all other samples returning negative results.

No new cases have been reported since September 15, 2023, marking the sixth outbreak of the Nipah virus in India since 2001. Nipah virus, a zoonotic disease, spreads to humans through contact with infected animals, such as bats and pigs, and less frequently, through direct contact with infected individuals [2]. Infection can cause severe symptoms including acute respiratory illnesses and fatal encephalitis. It is crucial to raise awareness about the risk factors and preventive measures to curb the spread of the virus. Case management should focus on providing supportive care and intensive treatment for the respiratory and neurological complications. To contain the outbreak, state and national authorities launched a coordinated response, including enhanced surveillance, contact tracing, laboratory testing, hospital preparedness, infection prevention and control measures, and community engagement initiatives [3].

## **EPIDEMIOLOGY**

The Nipah virus was first discovered in Malaysia in 1999 during an encephalitis outbreak among pig farmers who contracted the virus through close contact with infected pigs. Since then, NiV outbreaks have been reported in Bangladesh, India, and other countries. Fruit bats of the genus *Pteropus* are regarded as natural reservoirs of NiV, with human transmission primarily occurring through the consumption of contaminated fruits or direct contact with bat excreta.

Nipah virus infection in humans presents with a range of clinical symptoms such as acute respiratory illness and fatal encephalitis. During outbreaks in Bangladesh, India, Malaysia, and Singapore, case-fatality rates usually range from 40% to 100%. Currently, no effective treatments or vaccines are available for this disease.

The current outbreak in Kozhikode district, Kerala, is the third occurrence of a Nipah virus outbreak, the fourth within the state of Kerala since 2018, and the sixth across India as a whole [4]. Similar to the 2018 outbreak in Kerala, this outbreak was initiated with an index case followed by subsequent cases clustered among family contacts and likely nosocomial transmission within healthcare settings. Among the countries in the WHO South-East Asia Region, only Bangladesh and India have reported Nipah virus outbreaks.

## **TRANSMISSION**

Nipah virus can spread between people through direct contact with infected individuals or their bodily fluids, especially respiratory secretions. Transmission instances within healthcare facilities have been observed during outbreaks, emphasizing the crucial role of infection control measures in such settings. Additionally, NiV can spread via the consumption of contaminated food or water, although this route is less common [5].

## **CLINICAL MANIFESTATIONS**

Nipah virus infection may lead to various clinical symptoms such as fever, headaches, dizziness, respiratory issues, and encephalitis. Severe cases may progress to coma and respiratory failure with a high mortality rate observed during outbreaks. Neurological sequelae such as long-term cognitive impairment and seizures have been reported among survivors of NiV encephalitis, underscoring the need for comprehensive post-acute care.

Nipah virus infection can lead to varying degrees of illness, ranging from mild to severe, potentially resulting in brain swelling (encephalitis), and even death. Symptoms typically manifest within 4-14 days of exposure to the virus. Initially, the illness presents as fever and headache lasting 3-14 days, often accompanied by respiratory symptoms, such as cough, sore throat, and difficulty breathing. Subsequently, there may be a phase of encephalitis characterized by symptoms such as drowsiness, disorientation, and mental confusion, which can quickly progress to coma within 24-48 hours [6].

Initially, symptoms may manifest as one or a combination of fever, headache, cough, sore throat, difficulty breathing, and vomiting. Subsequently, severe symptoms may develop, including disorientation, drowsiness, confusion, seizures, coma, and brain swelling (encephalitis). The fatality rate ranged from 40% to 75%. Survivors of Nipah virus infection may experience long-term side effects including persistent convulsions and personality changes. Additionally, dormant or latent infections have been documented, with symptoms and potential fatalities occurring months or years after exposure.

### **DIAGNOSIS AND TREATMENT**

Diagnosing Nipah virus infection can be challenging owing to its nonspecific clinical presentation and the need for specialized laboratory testing, including molecular assays and serological methods. Early detection is crucial for implementing appropriate infection control measures and for initiating supportive care. Currently, there is no targeted antiviral treatment for NiV infection. Treatment primarily focuses on supportive care, aimed at easing symptoms and addressing complications.

### **PREVENTION AND CONTROL**

Preventing Nipah virus outbreaks requires a multifaceted approach that includes the surveillance of bat populations, early detection of cases, rapid response to outbreaks, and implementation of infection control measures in healthcare settings. Vaccines and antiviral drugs targeting NiV are under development, offering promising avenues for future prevention and treatment efforts [7]. Public education campaigns are also essential for raising awareness about the risks of NiV transmission and promoting preventive measures such as avoiding contact with sick animals and practicing good hygiene.

### **PUBLIC HEALTH EDUCATIONAL MESSAGES SHOULD EMPHASIZE:**

#### **Mitigating Bat-to-Human Transmission Risk**

It is essential to boil freshly gathered date palm juice and ensure thorough washing and peeling of fruits before eating them. Any fruits displaying evidence of bat bites should be discarded, and locations inhabited by bats should be steered clear of. By washing and peeling fruits before consumption, the potential for international transmission through contaminated fruits or fruit products can be mitigated.

#### **Minimizing Animal-to-Human Transmission Risk**

Wearing protective attire, such as gloves, is advisable when dealing with ill animals or their tissues, as well as during slaughtering and culling. Avoiding direct contact with infected pigs is advisable, and precautions should be taken regarding the presence of fruit bats when establishing new pig farms in endemic areas. Animal samples believed to be infected with the Nipah virus should be managed by skilled personnel in appropriately equipped laboratories [8].

#### **Reducing Human-to-Human Transmission Risk**

Close, unprotected physical contact with individuals infected with Nipah virus should be avoided. Regular handwashing after caring for or visiting sick individuals is also recommended. Healthcare professionals caring for patients with suspected or confirmed infections should follow infection prevention and control protocols, such as standard, contact, and droplet precautions. Prioritizing supportive care, particularly for severe respiratory and neurological complications, is crucial in case management. Implementing safe burial practices is vital for both confirmed and suspected cases of Nipah virus infections.

### **Infection Prevention and Control in Healthcare Settings**

Individuals suspected of being infected with Nipah virus should be isolated in well-ventilated solitary rooms equipped with dedicated patient amenities and toileting facilities. Healthcare personnel should adhere to contact and droplet precautionary measures when attending to patients, with airborne precautions necessary during procedures that generate aerosols. Routine cleaning and disinfection of patient rooms and frequently touched surfaces are essential along with proper waste management protocols.

It is important to note that the WHO's infection prevention and control advice for the Nipah virus is under review and pending updates. Additionally, the WHO advises against imposing travel or trade restrictions on India based on the current information regarding these events [9].

### **PUBLIC HEALTH RESPONSE**

The Department of Health and Family Welfare, State Government of Kerala, in collaboration with the Ministry of Health and Family Welfare, Government of India, and its affiliated institutions, including the Indian Council of Medical Research (ICMR), National Institute of Virology (NIV) in Pune, and National Institute of Epidemiology in Chennai, executed the following public health response measures.

#### **Coordination**

Various central multidisciplinary teams were deployed by the Department of Health & Family Welfare, Department of Health Research, and Department of Animal Husbandry to support the State and District administration in containment and mitigation efforts. Nineteen core committees were established to oversee activities, such as surveillance, sample testing, contact tracing, patient transportation, case management, logistics, training, risk communication, and community engagement. A dedicated control room with a call center was set up in the district to coordinate response activities.

#### **Surveillance and Contact Tracing**

Active house-to-house surveillance was conducted by district health authorities in designated containment zones. As of September 27, 2023, 53,708 houses had been surveyed. A total of 1288 contacts, including high-risk individuals, were identified and quarantined with ongoing follow-up. Testing was conducted for All high-risk contacts were tested. Movement restrictions, social distancing measures, and mandatory mask-wearing were enforced in public spaces in nine villages of the Kozhikode district. Major public events in the district are restricted to October 1, 2023. Neighboring districts and states are alerted to enhance surveillance.

#### **Laboratory Testing**

Suspected cases, environmental samples, and animal samples were tested at various laboratories, including the Regional Viral Research and Diagnostic Laboratory at the Government Medical College (GMC), Kozhikode, ICMR Mobile BSL-3 lab, NIV field unit in Alappuzha, and NIV in Pune. As of September 27, 2023, no environmental or animal samples, including bats, tested positive for the Nipah virus.

#### **Health Facility Preparedness**

Emergency departments and health facilities are equipped to handle suspected cases and emergencies. Isolation rooms, intensive care units (ICU), and ventilators were prepared to treat suspected cases as needed. Dedicated ambulances were used for patient transport.

#### **Infection Prevention and Control (IPC)**

Healthcare workers received training on IPC measures and adequate stocks of Personal Protective Equipment (PPEs) were provided. IPC practices strictly adhered to and audited.

#### **Logistic Management**

The State Government ensured adequate stocks of PPEs, drugs, and other logistics.

---

### **Dead Body Management**

Protocols for the transfer and management of dead bodies were established in compliance with the standard protocols and IPC precautions.

### **Risk**

**Communication and Community Engagement:** Various channels were utilized to initiate information, education, and communication activities, such as regular press releases and expert doctors delivering audio and video messages. Infodemic management strategies have also been implemented to combat misinformation. A call center was established to provide psychosocial support.

### **Animal Sector**

Samples of bats, animal droppings, and fruits were collected from the village in which the first case resided. All samples tested negative for the Nipah virus [10].

These public health response measures were implemented based on guidelines developed by the State Government, Government of India, WHO, and partners during the 2018 Nipah virus outbreak in Kerala.

### **Global Health Implications**

Nipah virus infection represents a significant public health concern, with implications for global health security. The potential for international spread, combined with the lack of specific treatment options and high case fatality rates, underscores the importance of preparedness and collaboration among countries and international organizations in preventing and controlling NiV outbreaks.

### **CONCLUSION**

Nipah virus infection is a complex zoonotic disease with serious implications for human health and global health. Understanding the epidemiology, transmission dynamics, clinical manifestations, diagnosis, treatment, and prevention of NiV are essential to mitigate its impact and safeguard public health. Continued research, surveillance, and investment in preventive measures are crucial for addressing the ongoing threat posed by the Nipah virus outbreaks.

### **BIBLIOGRAPHY**

1. Chua KB, Bellini WJ, Rota PA, Harcourt BH, Tamin A, Lam SK, et al. Nipah virus: A recently emergent deadly paramyxovirus. *Science*. 2000;288(5470):1432-5.
2. Gurley ES, Montgomery JM, Hossain MJ, Bell M, Azad AK, Islam MR, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. *Emerg Infect Dis*. 2007;13(7):1031-7.
3. Nipah virus – India. *Who.int*. 2018. Available from: <https://www.who.int/emergencies/disease-outbreak-news/item/07-august-2018-nipah-virus-india-en>
4. Harcourt BH, Tamin A, Ksiazek TG, Rollin PE, Anderson LJ, Bellini WJ, et al. Molecular characterization of Nipah virus, a newly emergent paramyxovirus. *Virology*. 2000;271(2):334-49.
5. Lo MK, Lowe L, Hummel KB, Sazzad HM, Gurley ES, Hossain MJ, et al. Characterization of Nipah virus from outbreaks in Bangladesh, 2008–2010. *Emerg Infect Dis*. 2012;18(2):248-55.
6. Ang BSP, Lim TCC, Wang L. Nipah virus infection. *J Clin Microbiol*. 2018;56(6):e01875-17.
7. Rahman MA, Hossain MJ, Sultana S, Homaira N, Khan SU, Rahman M, et al. Date palm sap-linked Nipah virus outbreak, Bangladesh. *Emerg Infect Dis*. 2012;18(2):1031-3.
8. Chadha MS, Comer JA, Lowe L, Rota PA, Rollin PE, Bellini WJ, et al. Nipah virus-associated encephalitis outbreak, Siliguri, India. *Emerg Infect Dis*. 2006;12(2):235-40.
9. Luby SP, Gurley ES, Hossain MJ. Transmission of human infection with Nipah virus. *Clin Infect Dis*. 2009;49(11):1743-8.
10. Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, Hossain MS, et al. Clinical presentation of Nipah virus infection in Bangladesh. *Clin Infect Dis*. 2008;46(7):977-84.